Sanders Morris Harris’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-6,158
| Closed | -$1.19M | – | 92 |
|
|
2026
Q1 | $1.19M | Buy |
+6,158
| New | +$1.19M | 0.19% | 105 |
|
|
2025
Q4 | – | Sell |
-6,190
| Closed | -$950K | – | 58 |
|
|
2025
Q3 | $950K | Buy |
+6,190
| New | +$937K | 0.13% | 115 |
|
|
2025
Q2 | – | Sell |
-6,465
| Closed | -$940K | – | 174 |
|
|
2025
Q1 | $940K | Hold |
6,465
| – | – | 0.15% | 96 |
|
|
2024
Q4 | $848K | Buy |
6,465
+279
| +5% | +$39.1K | 0.13% | 114 |
|
|
2024
Q3 | $964K | Hold |
6,186
| – | – | 0.16% | 95 |
|
|
2024
Q2 | $965K | Hold |
6,186
| – | – | 0.16% | 90 |
|
|
2024
Q1 | $838K | Buy |
6,186
+275
| +5% | +$36.4K | 0.15% | 105 |
|
|
2023
Q4 | $816K | Sell |
5,911
-275
| -4% | -$35.7K | 0.4% | 61 |
|
|
2023
Q3 | $823K | Hold |
6,186
| – | – | 0.17% | 88 |
|
|
2023
Q2 | $811K | Buy |
+6,186
| New | +$910K | 0.18% | 84 |
|
|
2021
Q3 | – | Sell |
-4,750
| Closed | -$569K | – | 311 |
|
|
2021
Q2 | $569K | Hold |
4,750
| – | – | 0.11% | 156 |
|
|
2021
Q1 | $472K | Sell |
4,750
-2,050
| -30% | -$206K | 0.1% | 166 |
|
|
2020
Q4 | $684K | Hold |
6,800
| – | – | 0.16% | 114 |
|
|
2020
Q3 | $744K | Buy |
6,800
+965
| +17% | +$107K | 0.2% | 105 |
|
|
2020
Q2 | $618K | Buy |
+5,835
| New | +$603K | 0.3% | 43 |
|
|
2020
Q1 | – | Sell |
-5,600
| Closed | -$475K | – | 161 |
|
|
2019
Q4 | $475K | Hold |
5,600
| – | – | 0.11% | 164 |
|
|
2019
Q3 | $494K | Buy |
5,600
+1,100
| +24% | +$95.4K | 0.12% | 143 |
|
|
2019
Q2 | $372K | Hold |
4,500
| – | – | 0.1% | 185 |
|
|
2019
Q1 | $364K | Hold |
4,500
| – | – | 0.18% | 75 |
|
|
2018
Q4 | $342K | Hold |
4,500
| – | – | 0.19% | 73 |
|
|
2018
Q3 | $356K | Hold |
4,500
| – | – | 0.17% | 86 |
|
|
2018
Q2 | $316K | Hold |
4,500
| – | – | 0.15% | 91 |
|
|
2018
Q1 | $315K | Hold |
4,500
| – | – | 0.13% | 98 |
|
|
2017
Q4 | $312K | Hold |
4,500
| – | – | 0.13% | 85 |
|
|
2017
Q3 | $305K | Hold |
4,500
| – | – | 0.13% | 95 |
|
|
2017
Q2 | $307K | Hold |
4,500
| – | – | 0.13% | 88 |
|
|
2017
Q1 | $280K | Hold |
4,500
| – | – | 0.1% | 104 |
|
|
2016
Q4 | $246K | Hold |
4,500
| – | – | 0.11% | 93 |
|
|
2016
Q3 | $296K | Hold |
4,500
| – | – | 0.09% | 115 |
|
|
2016
Q2 | $272K | Sell |
4,500
-19,435
| -81% | -$1.13M | 0.06% | 188 |
|
|
2016
Q1 | $1.35M | Buy |
+23,935
| New | +$1.44M | 0.23% | 99 |
|
Other funds holding AZN
EP
IA
Sanders Morris Harris's AZN Position: Q2 2026 in Review
Sanders Morris Harris sold out of AstraZeneca (AZN) in Q2 2026, closing a stake of 6,158 shares — an estimated $1.19M sold.
Sanders Morris Harris first reported a position in AZN in Q1 2016 and held it in 31 quarters. The position peaked at $1.35M in Q1 2016. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Sanders Morris Harris reported no remaining AstraZeneca position as of Q2 2026 after selling out during the quarter.
- Sanders Morris Harris sold 6,158 AstraZeneca shares in Q2 2026, an estimated $1.19M.
- Sanders Morris Harris first reported a position in AstraZeneca in Q1 2016 and held it in 31 quarters.
- Sanders Morris Harris's AstraZeneca position peaked at $1.35M in Q1 2016.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Sanders Morris Harris's 13F filing for Q2 2026, filed 7 Jul 2026.